U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Cannabis Clinical Research: Drug Master Files (DMFs) & Quality Considerations - 09/16/2020
  1. Drugs

Webcast | Virtual

Event Title
Cannabis Clinical Research: Drug Master Files (DMFs) & Quality Considerations
September 16, 2020

Date:
September 16, 2020

 

Slides

ABOUT

This webinar encourages the use of Drug Master Files (DMFs) and highlights quality considerations that have been issued recently in guidance to further support cannabis research. Cannabis related firms will learn how DMFs might be able to help address their concerns related to the disclosure of potentially proprietary information.

INTENDED AUDIENCE

  • Drug developers and researchers working in the cannabis space.
  • Growers of cannabis products used by drug developers and researchers who submit applications to FDA.

Topics Covered

  • DMFs in cannabis research
  • Quality guidance in cannabis research
  • FDA’s role in regulation of cannabis products
  • Cannabis drug development
  • Botanical raw materials

FDA SPEAKER

Cassandra Taylor, Ph.D.
Chemist, Botanical Review Team (BRT)
Office of Pharmaceutical Quality (OPQ) | CDER | FDA

FDA RESOURCES

 

Back to Top